CLLS Cellectis S.A. IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q4*2023-12-31 | 2023Q3*2023-09-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2020Q22020-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $16.73M | $8.06M | — | — | $178,000 | $1.31M | $11.18M | $2.90M |
| Cost of revenue | — | — | — | — | $55,000 | $329,000 | $11.75M | $5.83M |
| Gross profit | — | — | — | — | $123,000 | $978,000 | -$578,000 | -$2.93M |
| R&D expense | $23.08M | $23.52M | — | — | $22.20M | $25.63M | $31.15M | $22.86M |
| SG&A expense | $5.08M | $3.88M | — | — | $3.95M | $4.83M | $9.34M | $9.07M |
| Operating income | -$9.59M | -$17.21M | -$29.58M | -$20.67M | -$23.62M | -$27.31M | -$37.48M | -$33.03M |
| Interest expense | $19.70M | $16.65M | $17.56M | $1.62M | $16.28M | $1.69M | — | — |
| Pretax income | — | -$25.50M | — | — | — | — | — | — |
| Income tax | $0 | -$193,000 | $6,000 | $107,000 | $258,000 | $0 | $0 | $0 |
| Net income | -$23.74M | -$25.27M | -$41.80M | -$18.55M | -$11.71M | -$18.95M | -$39.92M | -$32.26M |
| EBITDA | — | — | — | — | — | -$22.20M | -$34.10M | -$30.88M |
| EPS (basic) | -0.24 | -0.28 | — | — | -0.20 | -0.42 | -0.88 | -0.76 |
| EPS (diluted) | -0.24 | -0.28 | — | — | -0.20 | -0.42 | -0.88 | -0.76 |
| Weighted avg. shares (diluted) | — | 89.85M | — | — | 55.58M | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $59.81M | $149.04M | $136.71M | — | $84.39M | $129.44M | $248.23M | $260.71M |
| Short-term investments | $136.10M | $119.00M | — | — | — | — | — | — |
| Receivables | $8.78M | $9.74M | $569,000 | — | $422,000 | $2.60M | $3.88M | $3.98M |
| Inventory | — | — | — | — | — | — | $2.47M | $5.71M |
| Current assets | — | — | — | — | — | $175.17M | $280.35M | $347.93M |
| PP&E, netmay include right-of-use assets (IFRS) | $42.79M | $50.37M | $54.68M | — | $59.23M | $76.52M | $79.48M | $52.65M |
| Intangibles | $1.15M | — | — | — | — | — | — | — |
| Total assets | $353.97M | $407.15M | $334.27M | $209.70M | $227.67M | $320.88M | $457.56M | $472.70M |
| Current liabilities | $167.43M | $159.63M | $155.14M | $43.95M | $42.05M | $55.28M | $51.45M | $53.05M |
| Total liabilities | $256.86M | $258.54M | $249.57M | $133.58M | $131.12M | $140.36M | $155.24M | $127.64M |
| Shareholders' equity | $97.11M | $148.61M | $84.69M | $76.12M | $96.56M | $168.93M | $275.87M | $307.61M |
| Shares outstanding | 100.33M | 100.09M | 71.75M | — | 55.58M | 45.51M | 45.46M | 42.49M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | $5.11M | $3.38M | $2.15M |
| Stock-based compensation | $1.28M | $830,000 | $5.13M | -$3.17M | $100,000 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.